Other Transaction Agreement - New antibacterials for hospital and biothreat pathogens: a portfolio paradigm
Award Notice Posted
- Solicitation number
- Not on record
- Agency
-
Immediate Office of the Secretary
Department of Health and Human Services
- Awarded
- to Glaxosmithkline, LLC
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HHSO100201300011C Federal IDV award
- NAICS code
- 541711 Research and Development in Biotechnology
- PSC
- Not on record
Notice details come from SAM.gov. Updated .
Notice text
The objective of the Other Transaction Agreement is to create collaboration between GSK and BARDA to evaluate the efficacy and safety of GSK’s portfolio of clinical stage antibacterial assets for treating hospital and biothreat infections. To support this objective, GSK will conduct non-clinical and clinical studies, and generate data to support biothreat indications. By mutual consent of GSK and BARDA, preclinical candidates may be included in order to facilitate their progress into the clinical portfolio.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity